Friday, May 27, 2022
DLH Holdings (DLHC)
Awarded Spot on OMNIBUS IV
DLH delivers improved health and readiness solutions for federal programs through research, development, and innovative care processes. The Company’s experts in public health, performance evaluation, and health operations solve the complex problems faced by civilian and military customers alike, leveraging digital transformation, artificial intelligence, advanced analytics, cloud-based applications, telehealth systems, and more. With over 2,300 employees dedicated to the idea that “Your Mission is Our Passion,” DLH brings a unique combination of government sector experience, proven methodology, and unwavering commitment to public health to improve the lives of millions. For more information, visit www.DLHcorp.com.
Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.
Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Award. DLH has been awarded a spot on the Department of Defense’s OMNIBUS IV ID/IQ multiple award contract to provide health-related research and development and support services. One of 56 awardees, DLH will compete for individual task orders across two of OMNIBUS IV’s market segments – Research & Development and Research & Development Support Services. The award is a testament to DLH’s expanded service capabilities as a result of the recent acquisitions, in our view.
OMNIBUS IV. The contract has a five-year base period and a five-year extension option, and, in aggregate, has a $10 billion ceiling for all awardees. Specific values will be allocated to contractors as task orders are competed and awarded. The contract covers medical simulation technology, research into infectious diseases and radiation effects, battlefield healthcare, clinical medicine, chemical and biological readiness, genomics and omics-based research, and science technologies….
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.